INKT (MiNK Therapeutics) Volatility: 111.56% (As of Jun. 27, 2026)


INKT MiNK Therapeutics Inc INKT
34 GF Score
Price $11.41
! 2 Warning Signs
View Full Analysis

What is MiNK Therapeutics Volatility?

MiNK Therapeutics INKT +2.56% 34 Volatility is 111.56% as of Jun. 27, 2026. GuruFocus rates INKT with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-27), MiNK Therapeutics's Volatility is 111.56%.

MiNK Therapeutics  (NAS:INKT) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

MiNK Therapeutics Volatility Related Terms

INKT vs PDSB, PMVP, EDSA: Volatility Comparison

For the Biotechnology subindustry, MiNK Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MiNK Therapeutics Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's Volatility falls into.


INKT
34GF Score
MiNK Therapeutics Inc INKT
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiNK Therapeutics  (NAS:INKT) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 111.56% mean?
MiNK Therapeutics (INKT) has a Volatility of 111.56% as of Jun. 27, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on MiNK Therapeutics and its competitors.
Is MiNK Therapeutics' Volatility too high?
MiNK Therapeutics' current Volatility is 111.56%. Overall, MiNK Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does MiNK Therapeutics' Volatility compare to PDSB and PMVP?
MiNK Therapeutics' Volatility of 111.56% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on MiNK Therapeutics and its competitors. MiNK Therapeutics's current Volatility is 111.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiNK Therapeutics stock overvalued right now?
MiNK Therapeutics (INKT) has a current Volatility of 111.56%. The current Volatility is 111.56%. MiNK Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For MiNK Therapeutics (INKT), the current Volatility is 111.56% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MiNK Therapeutics Business Description

Other Exchanges 6Q40:Germany
Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
34GF Score

Get the complete analysis for INKT

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.41
Price